LifeCyte Innovations, Inc.

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

LEEEUL BIO SCIENCEBiotechnology

69% match

Lin BioScience is a clinical-stage biopharmaceutical company that discovers and develops novel, first-in-class drug candidates for the treatment of cancer, eye diseases, and metabolic diseases. The company serves patients with significant unmet medical needs through targeted therapies such as oral treatments for dry age-related macular degeneration, Stargardt disease, and acute leukemia.

Acucela is a biotechnology company developing ophthalmic therapeutics for retinal diseases, including age-related macular degeneration and Stargardt disease. Its research has included visual-cycle modulators such as emixustat, aimed at treating degenerative eye conditions.

Bioscience Pharma Partners is a biotechnology company that develops therapeutics targeting chronic neuroinflammation in central nervous system disorders. The company's lead patented therapeutic, BPP-1001, is designed to address conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic head injuries.

Neurock Pharmaceuticals Inc.BiotechnologyUnited States

67% match

Neurotech Pharmaceuticals is a biotechnology company that develops transformative therapies for chronic eye diseases, utilizing its proprietary Encapsulated Cell Therapy platform. The company serves patients with conditions such as Macular Telangiectasia Type 2 by providing advanced treatments designed to protect against progressive vision loss.